PASG vs. ATHA, ALGS, VXRT, GNFT, SLDB, PSTX, BDTX, IPSC, CRBU, and CADL
Should you be buying Passage Bio stock or one of its competitors? The main competitors of Passage Bio include Athira Pharma (ATHA), Aligos Therapeutics (ALGS), Vaxart (VXRT), Genfit (GNFT), Solid Biosciences (SLDB), Poseida Therapeutics (PSTX), Black Diamond Therapeutics (BDTX), Century Therapeutics (IPSC), Caribou Biosciences (CRBU), and Candel Therapeutics (CADL). These companies are all part of the "biological products, except diagnostic" industry.
Athira Pharma (NASDAQ:ATHA) and Passage Bio (NASDAQ:PASG) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their dividends, earnings, profitability, institutional ownership, risk, valuation, community ranking, media sentiment and analyst recommendations.
In the previous week, Passage Bio had 1 more articles in the media than Athira Pharma. MarketBeat recorded 5 mentions for Passage Bio and 4 mentions for Athira Pharma. Passage Bio's average media sentiment score of 1.55 beat Athira Pharma's score of 1.00 indicating that Athira Pharma is being referred to more favorably in the media.
Athira Pharma currently has a consensus target price of $19.00, indicating a potential upside of 625.19%. Passage Bio has a consensus target price of $9.00, indicating a potential upside of 689.47%. Given Athira Pharma's higher possible upside, analysts clearly believe Passage Bio is more favorable than Athira Pharma.
Passage Bio received 30 more outperform votes than Athira Pharma when rated by MarketBeat users. Likewise, 66.67% of users gave Passage Bio an outperform vote while only 58.06% of users gave Athira Pharma an outperform vote.
Athira Pharma is trading at a lower price-to-earnings ratio than Passage Bio, indicating that it is currently the more affordable of the two stocks.
57.1% of Athira Pharma shares are owned by institutional investors. Comparatively, 53.5% of Passage Bio shares are owned by institutional investors. 19.8% of Athira Pharma shares are owned by company insiders. Comparatively, 4.3% of Passage Bio shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Athira Pharma has a beta of 2.83, suggesting that its stock price is 183% more volatile than the S&P 500. Comparatively, Passage Bio has a beta of 1.28, suggesting that its stock price is 28% more volatile than the S&P 500.
Athira Pharma's return on equity of -68.53% beat Passage Bio's return on equity.
Summary
Passage Bio beats Athira Pharma on 10 of the 14 factors compared between the two stocks.
Get Passage Bio News Delivered to You Automatically
Sign up to receive the latest news and ratings for PASG and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PASG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Passage Bio Competitors List
Related Companies and Tools
